Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02569476
Title BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors BeiGene
Indications

leukemia

B-cell lymphoma

Therapies

Obinutuzumab + Zanubrutinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.